Mon panier

Biotinylated Mouse Integrin alpha V beta 8 (ITGAV&ITGB8) Heterodimer Protein, His,Avitag™&Tag Free (MALS verified)

Avis des utilisateurs
Numéro de produit/spécification
Prix
Availability
Qté
IT8-M52W7-25ug
$360.00
In Stock - Delivery in 2-3 business days
IT8-M52W7-200ug
$1420.00
In Stock - Delivery in 2-3 business days
Total des articles Montant du produit$ 0

Détails du produit

  • Synonyms

    Integrin alpha V beta 8, ITGAV&ITGB8

  • Source

    Biotinylated Mouse ITGAV&ITGB8 Heterodimer Protein (IT8-M52W7) is expressed from human 293 cells (HEK293). It contains AA Phe 31 - Val 988 & Gly 22 - Leu 681 (Accession # P43406-1 & Q0VBD0-1).

    Predicted N-terminus: Phe 31 | Gly 22

    Request for sequence
  • Molecular Characterization

    Integrin alpha V beta 8 Structure

    Other Tags and Version Biotin & Other Labeled Version

    Biotinylated Mouse ITGAV&ITGB8 Heterodimer Protein is produced by co-expression of ITGAV and ITGB8, has a calculated MW of 114.2 kDa (ITGAV) & 77.5 kDa (ITGB8). Subunit ITGAV is fused with an acidic tail at the C-terminus and followed by a polyhistidine tag and an Avi tag (Avitag™) and subunit ITGB8 contains no tag but a basic tail at the C-terminus.The protein migrates as 135-145 kDa (ITGAV) and 75-85 kDa (ITGB8) under non-reducing (NR) condition (SDS-PAGE) due to glycosylation.

  • Labeling

    Biotinylation of this product is performed using Avitag™ technology. Briefly, the single lysine residue in the Avitag is enzymatically labeled with biotin.

  • Protein Ratio

    Passed as determined by the SABA assay / HABA assay / binding ELISA.

  • Purity

    >95% as determined by SDS-PAGE.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in 50 mM Tris, 150 mM NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

Les clients ont également consulté

Affichage des données

  • SDS-PAGE

    Integrin alpha V beta 8 SDS-PAGE

    Biotinylated Mouse ITGAV&ITGB8 Heterodimer Protein on SDS-PAGE under non-reducing (NR) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • SEC-MALS

    Integrin alpha V beta 8 SEC-MALS

    The purity of Biotinylated Mouse ITGAV&ITGB8 Heterodimer Protein (Cat. No. IT8-M52W7) is more than 85% and the molecular weight of this protein is around 195-245 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     Integrin alpha V beta 8 ELISA

    Immobilized Mouse Latent TGFB1, His Tag (Cat. No. TG1-M5245) at 2 μg/mL (100 μL/well) can bind Biotinylated Mouse ITGAV&ITGB8 Heterodimer Protein (Cat. No. IT8-M52W7) with a linear range of 1-20 ng/mL (QC tested).

    Protocol
  •  Integrin alpha V beta 8 ELISA

    Immobilized Human Latent TGFB1, His Tag (Cat. No. TG1-H524x) at 5 μg/mL (100 μL/well) can bind Biotinylated Mouse ITGAV&ITGB8 Heterodimer Protein (Cat. No. IT8-M52W7) with a linear range of 2-20 ng/mL (Routinely tested).

    Protocol

Avis des utilisateurs
Publier un commentaire

FAQ

  • product

    Can lyophilized proteins remain stable during room-temperature shipping or temporary room-temperature exposure?

    In general, lyophilized proteins remain stable during room-temperature shipping or temporary exposure to room-temperature conditions.


    Many ACROBiosystems recombinant proteins are supplied in lyophilized (freeze-dried) form. The lyophilization process effectively removes moisture from the product, helping reduce degradation-related reactions and improve protein stability during transportation and storage.


    To evaluate the stability of lyophilized proteins under normal temperature conditions, ACROBiosystems conducted a stability study on 11 representative lyophilized protein products at 37°C. The study demonstrated that these proteins maintained good quality stability after storage at 37°C for approximately 20 days. Based on these validation results, temporary room-temperature exposure during shipping or handling is generally not expected to have a significant impact on product quality or downstream application performance.


    To ensure optimal long-term stability, products should be stored according to the storage conditions specified in the product Certificate of Analysis (COA) upon receipt.


    Supporting Document


Introduction de fond

Integrin alpha V beta 8 (ITGAV & ITGB8 or ITGAVB8) is expressed in yolk sac, placenta, brain perivascular astrocytes, Schwann cells, renal glomerular mesangial cells and pulmonary epithelial cells. Unlike other alpha V integrins, ITGAVB8 does not appear to assume different activation states, and the cytoplasmic tail does not connect to the cytoskeleton. It binds ligands containing an RGD motif, including vitronectin, fibrin and the latency associated peptide (LAP) of the latent TGF-beta complex. High affinity binding of alpha V beta 8 to LAP allows proteolytic cleavage by MT1-MMP, which releases active TGF-beta. This mechanism differs from that of alpha V beta 6, the other alpha V integrin which can activate TGF-beta from latency through non-proteolytic mechanisms. Downstream effects of TGF-beta activation include control of cell growth and associated vascularization.

Progrès de frontière

 
Progrès du développement médicamenteux
  • Nom anglais:

    integrin alpha V/beta 8

  • Catégorie:

  • Nombre de médicaments répertoriés:

    0 Détails

  • Nombre de médicaments cliniques:

    3 Détails

  • Étape de développement la plus élevée:

    Phase 2 Clinical

Drug Candidate Licensing
More
  • Informations de base sur le produit
  • Détails du produit
  • Les clients ont également consulté
  • Affichage des données
  • Avis des utilisateurs
  • FAQ
  • Contexte